Dementia with Lewy Bodies Consortium

项目摘要 据估计，美国有超过140万人患有路易体 痴呆(LBD)，包括路易体痴呆(DLB)或帕金森病痴呆 (PDD)。LBD患者患有认知能力下降，有时与阿尔茨海默病(AD)有关， 以及帕金森氏病(PD)的运动和行为变化。不幸的是，诊断结果 LBD的诊断可能很困难，尤其是那些在以下情况下出现认知障碍的DLB患者 运动性或明显的行为改变。虽然LBD的诊断生物标记物有限，但最近 研究进展表明，测定路易体病理(LBP)和AD的病理改变 用生物流体生物标志物可能是可能的。 直到最近，阻碍LBD生物标记物开发的因素包括受试者数量较少， 缺乏系统的患者特征，未能进行纵向随访和尸检。 AD和PD都受益于一些大的“财团”，这些财团通过 利用几组研究中心的优势，将工作与标准化相结合 研究这种疾病的方法。阿尔茨海默病中心(ADC)就是一个很好的例子 该项目由美国国家老龄研究所资助，全美有30多个研究中心 各州已同意采用标准化的方法来诊断和定性患有 广告。其他类似的计划包括阿尔茨海默病合作研究(ADCS)，阿尔茨海默病 疾病神经成像倡议(ADNI)，国家神经疾病和中风研究所 (NINDS)帕金森病生物标记物计划(PDBP)和帕金森进展标记物 主动性(PPMI)。幸运的是，后两个PD计划包括了更系统的临床 评估和收集与帕金森病认知相关的生物体液和成像数据。在获得资金之前 对于路易体联盟(DLBC)的痴呆症，美国还没有类似的计划。 这项DLBC更新建议的目标是利用和扩大DLBC队列，以增加 受试者登记，持续的纵向系统评估，收集生物液和成像 数据，并最终进行尸检。作为一个更多由假设驱动的续签建议，DLBC将利用 从DLBC参与者那里收集纵向数据、成像和生物液，以专注于诊断， 进展和临床变异性。两名新的联合首席调查员和一些新的联合首席调查员 调查人员和合作者将加入DLBC，以加强对新的 假设驱动的目标。

Project Summary It has been estimated that over 1.4 million people in the United States suffer from Lewy body dementia (LBD), including both dementia with Lewy bodies (DLB) or Parkinson's disease with dementia (PDD). Patients with LBD suffer from cognitive decline, sometimes linked to Alzheimer's disease (AD), and the motor and behavioral changes seen in Parkinson's disease (PD). Unfortunately, the diagnosis of LBD can be difficult, particularly in those DLB patients that present with cognitive impairment prior to motor or marked behavioral changes. While diagnostic biomarkers for LBD have been limited, recent developments have suggested that determining Lewy body pathology (LBP) and AD pathology change may be possible with biofluid biomarkers. Until recently, impediments to biomarker development in LBD have included small subject numbers, a lack of systematic patient characterization and a failure to perform longitudinal follow up with autopsy. Both AD and PD have benefited from a number of large “consortiums” that have advanced research by leveraging the strengths of several groups of research centers to combine efforts with standardized approaches to the study of the disease. One good example is the Alzheimer's Disease Centers (ADC) program, funded by the National Institute on Aging, where over 30 research centers across the United States have agreed to a standardized approach to the diagnosis and characterization of patients with AD. Other similar programs include the Alzheimer's Disease Cooperative Study (ADCS), Alzheimer's Disease Neuroimaging Initiative (ADNI), the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarker Program (PDBP), and the Parkinson's Progression Marker Initiative (PPMI). Fortunately, the latter two PD programs have included more systematic clinical assessments and collection of biofluids and imaging data relevant to cognition in PD. Until funding of the Dementia with Lewy Body Consortium (DLBC), no similar US-based program had existed. The objective of this DLBC renewal proposal is to utilize and expand the DLBC cohort with additional subjects enrolled, continued longitudinal systematic assessments, collection of biofluids and imaging data, and ultimately autopsy. As a more hypothesis-driven renewal proposal, the DLBC will utilize the longitudinal data, imaging and biofluid collection from DLBC participants to focus on diagnosis, progression and clinical variability. Two new Co-Principal Investigators and a number of new co- investigators and collaborators will join the DLBC to enhance the additional focus on the new hypothesis-driven aims.